对代谢功能障碍相关的肥胖症和肥胖肝炎的务实管理方法
1Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
The American journal of gastroenterology
|November 21, 2024
概括
肥胖导致代谢功能障碍和肝病,如代谢功能障碍相关的脂肪性肝病 (MASLD). 一种新的基于风险的方法有助于评估和管理MASLD及其相关的健康威胁.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 非传染性疾病 非传染性疾病
背景情况:
- 肥胖和胰岛素抵抗导致慢性代谢炎症,导致器官功能障碍和2型糖尿病,高血压和MASLD等疾病.
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是MASLD的活性形式,炎症增加和纤维化进展为肝硬化.
- 现有的治疗方法旨在解决代谢炎症和预防纤维化,最近的批准和治疗方法越来越关注肥胖个体的肝脏健康.
研究的目的:
- 为评估和管理MASLD提供一个务实的,基于风险的方法.
- 整合对多种代谢并发症的MASLD患者的护理.
- 为满足对肥胖个体肝脏评估日益增长的需求.
主要方法:
- 基于风险的患者评估策略.
- 一个整体的方法来管理代谢并发病症.
- 关于MASLD和MASH管理的临床指南.
主要成果:
- 提出的方法有助于全面评估与MASLD相关的风险.
- 它可以为患有多种代谢威胁的患者提供综合护理规划.
- 它为在肥胖和代谢综合征的背景下管理肝病提供了一个框架.
结论:
- 基于风险的整体策略对于管理MASLD和相关代谢条件至关重要.
- 这种方法解决了患者护理的复杂性,将肝脏健康与整体代谢健康相结合.
- 为了有效管理MASLD,需要解决潜在的代谢炎症状态和相关的并发症.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
Diabetes: Management and Pharmacotherapy
236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Acute Pancreatitis II: Clinical Manifestations and Management
93
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
93
Overview of Lipid Metabolism
1.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.0K
Overview of Carbohydrate Metabolism
745
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
745
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
30
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
30


